Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.
Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Peta A, Ciolli S, Deplano W, Fabbiano F, Sica S, Di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F; GIMEMA Group. Annino L, et al. Among authors: vegna ml. Blood. 2002 Feb 1;99(3):863-71. doi: 10.1182/blood.v99.3.863. Blood. 2002. PMID: 11806988 Free article. Clinical Trial.
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.
Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, Mecucci C, Tedeschi A, Fioritoni G, Ferrara F, Di Raimondo F, Gallo E, Liso V, Fabbiano F, Cascavilla N, Pizzolo G, Camera A, Pane F, Lanza F, Cilloni D, Annino L, Vitale A, Vegna ML, Vignetti M, Foà R, Mandelli F; GIMEMA Group. Tafuri A, et al. Among authors: vegna ml. Blood. 2002 Aug 1;100(3):974-81. doi: 10.1182/blood-2001-12-0371. Blood. 2002. PMID: 12130511 Free article.
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.
Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Avvisati G, et al. Among authors: vegna ml. Blood. 2002 Nov 1;100(9):3141-6. doi: 10.1182/blood-2002-02-0352. Blood. 2002. PMID: 12384411 Free article. Clinical Trial.
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. Mandelli F, et al. Among authors: vegna ml. Blood. 1997 Aug 1;90(3):1014-21. Blood. 1997. PMID: 9242531 Free article. Clinical Trial.
Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia.
Mancini M, Vegna ML, Castoldi GL, Mecucci C, Spirito F, Elia L, Tafuri A, Annino L, Pane F, Rege-Cambrin G, Gottardi M, Leoni P, Gallo E, Camera A, Luciano L, Specchia G, Torelli G, Sborgia M, Gabbas A, Tedeschi A, Della Starza I, Cascavilla N, Di Raimondo F, Mandelli F, Foà R. Mancini M, et al. Among authors: vegna ml. Leukemia. 2002 Oct;16(10):2055-61. doi: 10.1038/sj.leu.2402640. Leukemia. 2002. PMID: 12357357
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Mauro FR, Zinzani P, Zaja F, Gentile M, Vegna ML, Stefoni V, Marin L, Fanin R, Baccarani M, Tura S, Mandelli F. Mauro FR, et al. Among authors: vegna ml. Haematologica. 2003 Dec;88(12):1348-57. Haematologica. 2003. PMID: 14687987 Clinical Trial.
Allogeneic or autologous bone marrow transplantation for intensification of salvage therapy in patients with high-risk advanced acute lymphoblastic leukemia. The AIEOP/GIMEMA Groups.
Arcese W, Amadori S, Meloni G, Giona F, Vegna ML, Testi AM, Annino L, Carotenuto M, Resegotti L, Madon E, et al. Arcese W, et al. Among authors: vegna ml. Semin Hematol. 1991 Jul;28(3 Suppl 4):116-21. Semin Hematol. 1991. PMID: 1780745 Clinical Trial. No abstract available.
Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA.
Avvisati G, Mandelli F, Petti MC, Vegna ML, Spadea A, Liso V, Specchia G, Bernasconi C, Alessandrino EP, Piatti C, et al. Avvisati G, et al. Among authors: vegna ml. Eur J Haematol. 1990 Apr;44(4):257-60. doi: 10.1111/j.1600-0609.1990.tb00389.x. Eur J Haematol. 1990. PMID: 2188854 Clinical Trial.
35 results